🇺🇸·20h agoIndustry
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Publisher
G
Gilead Sciences
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Gilead Sciences
- Region
- USA
- Scope
- Industry
- Published
- July 21, 2026
- Language
- EN
Topics
antiviraloncology
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on gilead.com
Leave the platform to read the original full article on the publisher site.
Source: Gilead Sciences
Scope: Industry
Related coverage
More related coverage
Techcyte/3h ago
Techcyte Marks 11 Million AI-Assisted Scans Across Its Global Platform
Nippon Shinyaku News/4h ago
譲渡制限付株式報酬としての自己株式の処分に関するお知らせ
Merck & Co. (MSD) News/5h ago
Investigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Takeda News/6h ago